Prima BioMed (IMMP) Competitors $2.04 -0.03 (-1.45%) Closing price 04:00 PM EasternExtended Trading$2.04 +0.00 (+0.25%) As of 04:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMMP vs. SYRE, PHVS, NBTX, PRAX, RLAY, SPRY, DNTH, LENZ, AMPH, and UPBShould you be buying Prima BioMed stock or one of its competitors? The main competitors of Prima BioMed include Spyre Therapeutics (SYRE), Pharvaris (PHVS), Nanobiotix (NBTX), Praxis Precision Medicines (PRAX), Relay Therapeutics (RLAY), ARS Pharmaceuticals (SPRY), Dianthus Therapeutics (DNTH), LENZ Therapeutics (LENZ), Amphastar Pharmaceuticals (AMPH), and Upstream Bio (UPB). These companies are all part of the "pharmaceutical products" industry. Prima BioMed vs. Its Competitors Spyre Therapeutics Pharvaris Nanobiotix Praxis Precision Medicines Relay Therapeutics ARS Pharmaceuticals Dianthus Therapeutics LENZ Therapeutics Amphastar Pharmaceuticals Upstream Bio Prima BioMed (NASDAQ:IMMP) and Spyre Therapeutics (NASDAQ:SYRE) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability. Which has stronger earnings & valuation, IMMP or SYRE? Prima BioMed has higher revenue and earnings than Spyre Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrima BioMed$6.69M44.88-$39.78MN/AN/ASpyre Therapeutics$890K1,594.15-$208.02M-$3.40-6.91 Which has more risk & volatility, IMMP or SYRE? Prima BioMed has a beta of 1.87, meaning that its stock price is 87% more volatile than the S&P 500. Comparatively, Spyre Therapeutics has a beta of 2.9, meaning that its stock price is 190% more volatile than the S&P 500. Is IMMP or SYRE more profitable? Prima BioMed's return on equity of 0.00% beat Spyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Prima BioMedN/A N/A N/A Spyre Therapeutics N/A -71.30%-38.69% Do institutionals & insiders hold more shares of IMMP or SYRE? 2.3% of Prima BioMed shares are held by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are held by institutional investors. 3.1% of Prima BioMed shares are held by insiders. Comparatively, 6.2% of Spyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media refer more to IMMP or SYRE? In the previous week, Spyre Therapeutics had 15 more articles in the media than Prima BioMed. MarketBeat recorded 17 mentions for Spyre Therapeutics and 2 mentions for Prima BioMed. Spyre Therapeutics' average media sentiment score of 0.64 beat Prima BioMed's score of 0.00 indicating that Spyre Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prima BioMed 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spyre Therapeutics 3 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate IMMP or SYRE? Prima BioMed currently has a consensus target price of $7.00, indicating a potential upside of 243.14%. Spyre Therapeutics has a consensus target price of $54.29, indicating a potential upside of 131.10%. Given Prima BioMed's higher possible upside, research analysts plainly believe Prima BioMed is more favorable than Spyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prima BioMed 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Spyre Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.00 SummarySpyre Therapeutics beats Prima BioMed on 9 of the 14 factors compared between the two stocks. Get Prima BioMed News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMMP vs. The Competition Export to ExcelMetricPrima BioMedMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$300.27M$3.46B$6.17B$10.68BDividend YieldN/A2.27%5.72%4.83%P/E RatioN/A23.2129.4127.38Price / Sales44.88479.02588.00132.78Price / CashN/A45.2825.8230.35Price / Book3.2410.5412.496.68Net Income-$39.78M-$52.62M$3.32B$276.27M7 Day Performance2.51%4.90%2.38%0.95%1 Month Performance26.71%15.97%8.71%3.92%1 Year Performance2.51%14.17%61.90%36.33% Prima BioMed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMMPPrima BioMed0.7085 of 5 stars$2.04-1.4%$7.00+243.1%+4.0%$300.27M$6.69M0.002,021News CoverageHigh Trading VolumeSYRESpyre Therapeutics2.916 of 5 stars$18.92-1.1%$54.29+186.9%-31.4%$1.16B$890K-5.5673PHVSPharvaris2.6814 of 5 stars$22.07+0.4%$32.60+47.7%-0.4%$1.15BN/A-6.5730Positive NewsAnalyst RevisionNBTXNanobiotix0.8298 of 5 stars$30.31+28.4%$11.00-63.7%+441.2%$1.13B$39.18M0.00100Short Interest ↑PRAXPraxis Precision Medicines2.5306 of 5 stars$52.34-1.7%$85.56+63.5%+159.5%$1.12B$8.55M-4.26110Analyst ForecastRLAYRelay Therapeutics2.2001 of 5 stars$6.27-3.5%$16.50+163.2%-3.6%$1.12B$10.01M-3.22330SPRYARS Pharmaceuticals3.0145 of 5 stars$10.93-3.4%$33.80+209.2%-37.1%$1.12B$89.15M-22.3190Positive NewsDNTHDianthus Therapeutics2.9467 of 5 stars$34.42-0.1%$61.57+78.9%+22.7%$1.11B$6.24M-10.5980LENZLENZ Therapeutics2.3677 of 5 stars$38.61-0.5%$52.80+36.8%+36.7%$1.11BN/A-20.32110Analyst ForecastGap UpAMPHAmphastar Pharmaceuticals4.7419 of 5 stars$23.51-0.5%$31.60+34.4%-53.2%$1.10B$731.97M8.812,028Positive NewsUPBUpstream Bio1.9856 of 5 stars$20.08+2.3%$56.50+181.4%-19.0%$1.06B$2.37M0.0038 Related Companies and Tools Related Companies Spyre Therapeutics Alternatives Pharvaris Alternatives Nanobiotix Alternatives Praxis Precision Medicines Alternatives Relay Therapeutics Alternatives ARS Pharmaceuticals Alternatives Dianthus Therapeutics Alternatives LENZ Therapeutics Alternatives Amphastar Pharmaceuticals Alternatives Upstream Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMMP) was last updated on 10/20/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredThis dark force is about to change everythingSomething unusual is unfolding inside the Republican Party — from Marjorie Taylor Greene breaking ranks to Ted...Porter & Company | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredWhat Wall Street Won’t Say Out LoudDiscover the 7 key indicators before everyone else doesAmerican Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prima BioMed Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Prima BioMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
